Related Experiment Video
Updated: Aug 30, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer
Patricia Mae G Santos1, Xingzhe Li1, Daniel R Gomez1
1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Abstract:
In the last 20 years, significant strides have been made in our understanding of the biological mechanisms driving disease pathogenesis in metastatic non-small cell lung cancer (NSCLC). Notably, the development and application of predictive biomarkers as well as refined treatment regimens in the form of chemoimmunotherapy and novel targeted agents have led to substantial improvements in survival. Parallel to these remarkable advancements in modern systemic therapy has been a growing recognition of "oligometastatic disease" as a distinct clinical entity-defined by the presence of a controlled primary tumor and ≤5 sites of metastatic disease amenable to local consolidative therapy (LAT), with surgery or stereotactic ablative body radiotherapy (SABR). To date, three randomized studies have provided clinical evidence supporting the use of LAT/SABR in the treatment of oligometastatic NSCLC. In this review, we summarize clinical evidence from these landmark studies and highlight ongoing trials evaluating the use of LAT/SABR in a variety of clinical contexts along the oligometastatic disease spectrum. We discuss important implications and caveats of the available data, including considerations surrounding patient selection and application in routine clinical practice. We conclude by offering potential avenues for further investigation in the oligometastatic disease space.
Insights
Local consolidative therapy (LAT) shows promise for oligometastatic non-small cell lung cancer (NSCLC). This review examines evidence supporting LAT, including surgery or stereotactic ablative radiotherapy (SABR), for select NSCLC patients.
Area of Science:
- Oncology
- Pulmonology
- Radiation Oncology
Background:
- Significant advances in understanding metastatic non-small cell lung cancer (NSCLC) pathogenesis over 20 years.
- Improved survival in NSCLC due to predictive biomarkers, chemoimmunotherapy, and targeted agents.
- Emerging recognition of oligometastatic disease as a distinct clinical entity.
Purpose of the Study:
- To review clinical evidence supporting local consolidative therapy (LAT) for oligometastatic NSCLC.
- To summarize findings from landmark randomized studies on LAT/SABR.
- To highlight ongoing trials and discuss implications for clinical practice.
Main Methods:
- Review of clinical evidence from three randomized studies on LAT/SABR in oligometastatic NSCLC.
- Summary of ongoing clinical trials evaluating LAT/SABR.
- Discussion of patient selection and clinical application considerations.
Main Results:
- Three randomized studies provide clinical evidence supporting LAT/SABR for oligometastatic NSCLC.
- Ongoing trials are exploring LAT/SABR across the oligometastatic disease spectrum.
- Data suggests potential benefits but requires careful patient selection and consideration for routine use.
Conclusions:
- LAT, including surgery and stereotactic ablative body radiotherapy (SABR), is a viable option for select oligometastatic NSCLC patients.
- Further investigation is needed to refine patient selection and optimize the application of LAT in clinical practice.
- Future research should explore novel approaches within the oligometastatic disease space.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy